The 340B program has received its share of criticisms, largely due to the lack of transparency into covered entities who ...

Bristol Myers Squibb has sued the Biden administration over payment terms for hospitals in the 340B Drug Discount Program.

Bristol Myers Squibb is the latest pharma company to sue the federal government over its rejection of a proposed new model ...

The federal 340B Drug Pricing Program — a noble idea first enacted in 1992 — needs to be brought back into the shop for ...

Discover how the 340B drug pricing program, intended to help low-income patients, has become a system of abuse and misuse ...

Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top ...

The 340B program's “covered entities” serve low-income, poorer populations that tend to be un- or underinsured. Many, if not ...

Minnesota releases a report on the 340B Drug Pricing Program, highlighting the need for transparency in healthcare economics.

Learn about the legal battle between Bristol Myers Squibb and the HHS over the 340B drug pricing program, as other drugmakers join in with rebate plans.

The aims of the 340B program are important. But, unfortunately, there is little evidence that the program is delivering on ...

Minnesota has becomes the first state to release a report examining the 340B drug discount program for "safety-net" hospitals ...

Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead ...